Edesa Biotech Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical-stage drugs for dermatological and gastrointestinal indications. Its lead product candidate, EB01, is an sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD). Its pipeline also includes EB02 and EB04. EB02, an sPLA2 inhibitor, is being developed as a treatment for patients with hemorrhoids disease (HD). EB04 is being developed for anal fissures. It is also focused on developing biologic drug candidates for therapeutic, prophylactic and diagnostic applications.